Stroke

The ZEISS INTRABEAM 700 advances neurosurgical oncology by enabling precise intraoperative radiotherapy delivery, improved workflow efficiency, and enhanced collaboration between neurosurgeons and oncologists.

Among patients with BAD, 20.4% on argatroban plus DAPT experienced early neurological deterioration vs 47.1% on DAPT alone, and 87.8% vs 68.6% achieved excellent 90-day outcomes.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on stroke in epilepsy.

High doses of RNS60 led to greater number of patients with modified Rankin scale scores between 0-2, improved EQ-5D-5L index score, and enhanced NIHSS score at each pre-specified time point over placebo.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 11, 2025.

Cleveland Clinic’s $1.1 billion Neurological Institute, opening in 2027, will revolutionize neurological care with a state-of-the-art, patient-centered design integrating advanced technology and innovative care solutions.

Catch up on any of the neurology news headlines you may have missed over the course of March 2025, compiled all into one place by the NeurologyLive® team.

The clinical professor of stroke neurology at Stanford University discussed the clinical rationale and evidence supporting early, intensive blood pressure lowering in patients with intracerebral hemorrhage.

AHN Neuroscience Institute is the first in western Pennsylvania to offer the FDA-approved Vivistim device, combining vagus nerve stimulation with traditional rehab to improve stroke recovery.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 14, 2025.

Explore the key 2024 neurology guideline updates shaping clinical care across stroke, epilepsy, movement disorders, and more in this essential feature.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 7, 2025.

The thrombolytic treatment, branded as TNKase and approved for adults, is administered as a 5-second IV bolus, upping the speed and simplicity of the 60-minute infusion of the previously approved alteplase (Activase; Genentech).

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 28, 2025.

RapidAI identified 98% of LVOs compared to 74% by Viz LVO, while also correctly identifying 94% of LVO-negative cases compared to 91% for Viz.

Propranolol showed a stronger protective effect against ischemic stroke compared to other beta-blockers, such as metoprolol and timolol, possibly due to its unique pharmacological profile.

ANGEL-TNK demonstrated Tenecteplase's potential to enhance microcirculation post-thrombectomy, reducing brain tissue damage from inadequate blood flow.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 21, 2025.

A pair of lead neurologists at Baptist Health South Florida provided commentary on some of the promising developments expected to emerge in neurology over the coming months.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 14, 2024.

Andrei Alexandrov, MD, chair of the department of neurology at the University of Arizona College of Medicine, covered the latest advancements in stroke care from ISC 2025, from expanding thrombectomy indications to evolving imaging techniques.

Stroke neurologists Lauren Sansing, MD, MS, FAHA, FANA, and Bijoy Menon, MD, MSc, FRCPC, provided a post-conference perspective on the emerging data and research presented at the 2025 International Stroke Conference.

The director of the Cerebrovascular Center at Mount Sinai talked about findings from recent trials presented at ISC 2025 investigating thrombectomy for distal vessel occlusions. [WATCH TIME: 4 minutes]

The professor and chair of the neurology department at the University of Arizonia, Phoenix, gave clinical insights on the notable progress in the stroke treatment world, highlighted by advances presented at the 2025 International Stroke Conference. [WATCH TIME: 3 minutes]

The professor at the Second Affiliated Hospital of Zhejiang University’s School of Medicine discussed findings from a trial suggesting that intravenous thrombolysis could benefit patients with ischemic stroke up to 24 hours after symptom onset. [WATCH TIME: 8 minutes]

The director of the neurological disease center at Beijing Anzhen Hospital talked about assessing the potential benefits and safety of intra-arterial tenecteplase in highly selected poststroke patients. [WATCH TIME: 6 minutes]

In addition to failing to separate itself on the primary end point, EVT + best medical care was associated with higher rates of serious adverse events (33.9% vs 25.7%) and mortality (13.3% vs 8.4%) compared to best medical care alone.

The group of women neurologists provided commentary on the critical areas of women-focused research in neurology, from clinical trial participation to addressing workforce challenges.

In a recently presented study at ISC 2025, poststroke patients reported no additional benefit from using transcranial direct current stimulation as a potential intervention for recovery.